AVANIR Pharmaceuticals Invites Investors to Listen to the 2006 UBS Global Life Sciences Conference Webcast
Posted on: Thursday, 14 September 2006, 18:00 CDT
AVANIR Pharmaceuticals (NASDAQ:AVNR) will be presenting at the 2006 UBS Global Life Sciences Conference on Wednesday, September 27, 2006 at 11:30 a.m. EDT in New York, New York. AVANIR's President and Chief Executive Officer, Eric K. Brandt, will be presenting at the investor conference.
The presentation will be available via a live webcast accessible through AVANIR's corporate website at www.avanir.com. To access the webcast, log on to AVANIR's site fifteen minutes prior to the presentation to register and download any necessary audio software. An archive of the presentation will be available for 90 days following the event.
About AVANIR
AVANIR Pharmaceuticals is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases
. AVANIR's products and product candidates address therapeutic markets that include the central nervous system, cardiovascular disorders, inflammation and infectious diseases. AVANIR currently markets FazaClo(R), the only orally-disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who fail to respond adequately to standard schizophrenic drug treatments. FazaClo is also indicated for reducing the risk of suicidal behavior in patients with schizophrenic or schizoaffective disorder. For full prescribing information and important safety information regarding FazaClo, please visit www.fazaclo.com AVANIR's lead product candidate, Neurodex(TM) for the treatment of involuntary emotional expression disorder, is the subject of a New Drug Application under priority review with the FDA. Additionally, AVANIR has initiated a Phase III clinical trial with Neurodex as a potential treatment for patients with painful diabetic neuropathy. AVANIR has active collaborations with two international pharmaceutical companies: Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease and AstraZeneca for the treatment of cardiovascular disease. The Company's first commercialized product, abreva(R), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.Source: Business Wire
Related Articles
- Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients
- RHEI Pharmaceuticals Receives Approval in China for Its Drs. Hans Schreuder Scar Treatment Product
- Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
- Sciele Pharma to Webcast Product Development Pipeline Presentation
- Pfizer's Celsentri(R) Approved in the European Union, Providing a Novel Treatment Option for Treatment-Experienced HIV Patients
- New Data Confirm Durable Response of TNX-355 Regimens Through 48 Weeks in Treatment-Experienced HIV Patients
- China Provides Free Treatment to TB Patients
- New Planning Tool Streamlines Brachytherapy Treatments and Improves Patient Comfort
- Coronary Artery Dilation Among Patients Presenting With Systemic- Onset Juvenile Idiopathic Arthritis
- Invasive Treatment May Be More Effective for Heart Attack Patients Presenting Late to Hospital
 |
 |
User Comments (0)
RSS Feeds